On Tuesday, Simulations Plus, Inc. (NASDAQ:SLP) shares price traded between $31.71 and $32.86 during the last trading session above/below with -0.06% at $31.89. The shares recorded a trading volume 153,389 shares as compared to its average volume of 70,888 shares. Analysts mean Recommendation on a stock is noted at 2.00. Analyst Recommendation is an outlook of a stock-market analyst on a stock. Rating Scale: 1.0 represent “Strong Buy” and 2.0 signify “Buy” 3.0 while shows “Hold”. 4.0 display “Sell” and 5.0 reveal “Strong Sell” rating. The stock as of last trading session moved 86.49% up from its 52 week low and was -2.92% behind its 52 week high.
Simulations Plus, Inc. (SLP) recently reported that it has entered into a new five-year Research Alliance Contract with the U.S. Food and Drug Administration’s (FDA) Center for Veterinary Medicine to evaluate alternative approaches for determining product bioequivalence (BE) for locally-acting drugs in animals. “It is always exciting to announce ground-breaking collaborations with the FDA and reinforce our joint venture as we advance science in new areas,” stated Viera Lukacova, director of Simulation Sciences for Simulations Plus and principal investigator on the project. “Under this contract, the FDA, using GastroPlus with in vitro and in vivo data, will investigate how BE of non-systemically absorbed products can be evaluated in canines without the need for clinical endpoint trials. Ideally, through verification of the methods and results, a framework can be provided to support these approaches for other drugs.”
John DiBella, Lancaster division president for Simulations Plus, added, “Our technology is already assisting companies and regulatory agencies with the ‘3 Rs’: reducing, replacing, and/or refining animal use. We look forward to these interactions with the FDA staff to better understand model performance on additional veterinary medicines and identify further advances to the GastroPlus platform to support biowaiver applications.”
The P/E ratio was recorded at 72.97.The volatility in the previous week has experienced by 4.98% and observed of 3.98% in the previous month.44.00% ownership is held by institutional investors while insiders hold ownership of 29.90%.
Simulations Plus, Inc. (SLP) recently reported that it has entered into a new five-year Research Alliance Contract with the U.S. Food and Drug Administration’s (FDA) Center for Veterinary Medicine to evaluate alternative approaches for determining product bioequivalence (BE) for locally-acting drugs in animals. “It is always exciting to announce ground-breaking collaborations with the FDA and reinforce our joint venture as we advance science in new areas,” stated Viera Lukacova, director of Simulation Sciences for Simulations Plus and principal investigator on the project. “Under this contract, the FDA, using GastroPlus with in vitro and in vivo data, will investigate how BE of non-systemically absorbed products can be evaluated in canines without the need for clinical endpoint trials. Ideally, through verification of the methods and results, a framework can be provided to support these approaches for other drugs.”
John DiBella, Lancaster division president for Simulations Plus, added, “Our technology is already assisting companies and regulatory agencies with the ‘3 Rs’: reducing, replacing, and/or refining animal use. We look forward to these interactions with the FDA staff to better understand model performance on additional veterinary medicines and identify further advances to the GastroPlus platform to support biowaiver applications.”
The P/E ratio was recorded at 72.97.The volatility in the previous week has experienced by 4.98% and observed of 3.98% in the previous month.44.00% ownership is held by institutional investors while insiders hold ownership of 29.90%.
)
